1 |
Calfee, J. E. (2002). Public policy issues in direct-toconsumer advertising of prescription drugs. Journal of Public Policy & Marketing, 21(Fall), 174-193.
DOI
ScienceOn
|
2 |
Creyer, E. H., Hrsistodoulakis, I., & Cole, C. A. (2001). Changing a drug from Rx to OTC status: the consumer behavior and public policy implications of switch drugs. Journal of Product and Brand Management, 10(1), 52-64.
DOI
ScienceOn
|
3 |
Donohue, J. (2006). Direct-to-consumer advertising of prescription drugs: Does it add to the overuse and inappropriate use of prescription drugs or alleviate under-use? International Journal of Pharmaceutical Medicine, 20(1), 17-24.
DOI
ScienceOn
|
4 |
Hoek, J., Gendall, P., Rapson, L., & Louviere, J. (2011). Information accessibility and consumers' knowledge of prescription drug benefits and risks. Journal of Consumer Affairs, 45(2), 248-274.
DOI
ScienceOn
|
5 |
Food and Drug Administration. (2002). Claritin approval marks significant shift in Rx-to-OTC switches. The Food & Drug Letter, Issue No. 666.
|
6 |
Frosch, D. L, Grande, D., Tam, D. M., & Kravitz, R. L. (2010). A decade of controversy: Balancing policy with evidence in the regulation of prescription drug advertising. American Journal of Public Health, 100(1), 24-32.
DOI
ScienceOn
|
7 |
Kaphingst, K. A., & DeJong, W. (2004). The educational potential of direct-to-consumer prescription drug advertising. Health Affairs, 23(4), 143-150.
DOI
ScienceOn
|
8 |
Kelly, P. (2004). Perspective: DTC advertising's benefits far outweigh its imperfections. Health Affairs, w4, 246-248.
|
9 |
Korea Food and Drug Administration (2011). Press release: KFDA's perspective on Rx-to-OTC switch, from http://www.kfda.go.kr/index.kfda?mid=56&pageNo=8&seq=15808&cmd=v
|
10 |
Lexchin, J. (1999). Direct-to-consumer advertising: Impact on patient expectations regarding disease management. Disease Management and Health Outcomes, 5(May), 273-283.
DOI
|
11 |
Avery, R., Kenkel, D., Lillard, D., & Alan M. (2007a). Regulating advertisements: The case of smoking cessation products. Journal of Regulatory Economics, 31(2), 185-208.
DOI
ScienceOn
|
12 |
Avery, R., Kenkel, D., Lillard, D., & Alan M. (2007b). Private profits and public health: Does advertising smoking cessation products encourage smokers to quit? Journal of Political Economy, 115(3), 447-481.
DOI
ScienceOn
|
13 |
Morris, L., Brinberg, D., Klimberge, R., Rivera, C., & Millstein, L. (1986). The attitudes of consumers toward direct advertising of prescription drugs. Public Health Report, 101(1), 82-89.
|
14 |
Ling, D., Berndt, E., & Kyle, M. (2002). Deregulating direct to consumer marketing of drugs: Effects on prescription and over-the-counter product sales. The Journal of Law and Economics, 45(2), 691-723.
DOI
ScienceOn
|
15 |
Meek, C. (2001). Direct-to-Consumer Advertising of Prescription Medicines: A Review of International Policy and Evidence. London: Royal Pharmaceutical Society of Great Britain.
|
16 |
Morris, L., Ruffner, M., & Klimberg, R. (1985). Warning disclosures for prescription drugs, Journal of Advertising Research, 25(October-December), 25-32.
|
17 |
Myers, S. D., Royne, M. B., & Deitz, G. D. (2011). Direct-to-consumer advertising: exposure, behavior, and policy implications. Journal of Public Policy & Marketing, 30(1), 110-118.
DOI
ScienceOn
|
18 |
Toop, L., Richards, D., Dowell, T., Tilyard, M., Fraser, T., & Arroll, B. (2003). DTCA in New Zealand - Report to Minister of Health Supporting the Ban on DTCA.
|